TCT 2025 - Findings from INFINITY-SWEDEHEART show significant reductions in target vessel failure and treatment benefit after 6 months to two years with the DynamX bioadaptor stent.

Prof David Erlinge (Skane University Hospital, SE) joins us to discuss findings from the INFINITY-SWEDEHEART trial, a prospective, multicenter, registry-based randomized clinical trial comparing long-term outcomes of the DynamX Bioadaptor to the Resolute Onyx drug-eluting stent in an all-comer percutaneous coronary intervention patient population.

This Swedish national registry-based trial randomized 2,400 patients with chronic coronary syndrome or acute coronary syndrome requiring percutaneous intervention across 19 centers throughout Sweden. Patients were randomized 1:1 to receive either the DynamX sirolimus-eluting coronary bioadaptor or the Resolute Onyx zotarolimus-eluting stent. The study leveraged Sweden's clinical registries for follow-up, with patients monitored through phone contact at 30 days and one year, and through national diagnostic registries from six months through five years, evaluating device-oriented and patient-oriented clinical endpoints.

Key findings demonstrated a 48% reduction in TLF rate, a significant reduction in target vessel failure and substantial benefits for high-risk patients with ACS after 6 months through 2 years in favour of the bioadaptor stent.

Interview Questions: 
1. What is the background of this trial?
2. Please remind us of the design and patient inclusion criteria?
3. What are the key results presented at TCT 25?
4. What is the take-home message for practice?
5. What are the next steps for bioadaptor research, and what will longer-term follow-up data reveal?

For more content from TCT 2025 head to the Late-breaking Science Video Collection.

Recorded on-site at TCT 2025, San Francisco

Editors: Jordan Rance, Mirjam Boros
Videographer: Tom Green, Mike Knight

Support: This is an independent interview produced by Radcliffe Cardiology.